Search Results - (Author, Cooperation:Crinis)
-
1Articles: DFG German National LicensesNeureiter, V. ; Schönberg ; Ehrismann ; Romanese ; Wachholz ; Lendle ; Schönheimer ; Engelhardt ; Scholz, H. ; Borger ; Peiser, B. ; Fröhlich, A. ; Heidepriem, Curt ; Neubauer, E. ; Prissmann, J. ; Loewenthal ; Wilder, Josef ; Reuter, Karl ; Stern, F. ; List ; Weimann ; Laubender, Walther ; Jendralski, F. ; Crinis, M. ; Crinis
Springer
Published 1931Staff ViewISSN: 1437-1596Source: Springer Online Journal Archives 1860-2000Topics: MedicineLawType of Medium: Electronic ResourceURL: -
2Articles: DFG German National LicensesStaff View
ISSN: 0378-4347Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
3Articles: DFG German National LicensesDittrich ; Leibbrand ; Tómasson, Helgi ; Wachholz, L. ; Wermer ; Merkel, H. ; Enke ; Pfister, H. ; Meixner ; Gruber, Georg B. ; Matwejeff, S. ; Crinis, M. ; Adam ; Derichsweiler ; Meyer, R. ; Snoo ; v. Neureiter ; Fraenckel, P. ; Hammer ; Friedl ; Klein, R. ; Ganter ; Ziemke ; Kolb ; Landé, K.
Springer
Published 1935Staff ViewISSN: 1437-1596Source: Springer Online Journal Archives 1860-2000Topics: MedicineLawType of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesStaff View
ISSN: 1434-4726Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesKeim ; Schwarz ; Wohlwill, Fr. ; Sieke ; Hári, Paul ; Makai, Endre ; Teleky ; Pette ; Peiser, Bruno ; Merkel, H. ; Schilf ; Meixner ; Neumann ; Walcher ; Krapf, Eduard ; Schmitz ; Strigel ; Schoen, R. ; Hamburger ; Strauss ; Romanese ; Crinis ; Bachstez ; Hofmeier, K. ; Fröhlich, A.
Springer
Published 1928Staff ViewISSN: 1437-1596Source: Springer Online Journal Archives 1860-2000Topics: MedicineLawType of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesNeureiter ; Schönberg ; Ehrismann ; Romanese ; Wachholz ; Lendle ; Schönheimer ; Engelhardt ; Borger ; Peiser, B. ; Fröhlich, A. ; Heidepriem, Curt ; Scholz, H. ; Neubauer, E. ; Prissmann, J. ; Loewenthal ; Wilder, Josef ; Reuter, Karl ; Stern, F. ; List ; Weimann ; Laubender, Walther ; Jendralski, F. ; Crinis, M.
Springer
Published 1931Staff ViewISSN: 1437-1596Source: Springer Online Journal Archives 1860-2000Topics: MedicineLawType of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesStaff View
ISSN: 1432-1459Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesStaff View
ISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesStaff View
ISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesStaff View
ISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
11Articles: DFG German National LicensesWebster, L. K. ; Crinis, Nicholas A. ; Morton, Carmel G. ; Millward, Michael J.
Springer
Published 1996Staff ViewISSN: 1432-0843Keywords: Key words Paclitaxel ; Drug interaction ; EthanolSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Paclitaxel is formulated in 50% Cremophor EL and 50% ethanol such that patients receiving paclitaxel also receive a significant amount of each of these solvents. The aim of this study was to measure the plasma alcohol levels in patients treated with paclitaxel. A total of 12 patients who were enrolled in phase II trials of non-small-cell lung cancer, breast cancer or ovarian cancer received 175 mg/m2 paclitaxel given as a 3-h infusion. Blood samples were obtained prior to and immediately following the infusion, and plasma ethanol concentrations were measured enzymatically. The dose of ethanol delivered with the paclitaxel ranged from 20.0 to 28.9 ml. No alcohol was detected in pre-dose plasma, but 8 of 12 patients had detectable levels in post-infusion plasma, with 0.033 g/dl being the highest concentration. The elimination rate of alcohol approximates the infusion rate when paclitaxel is given over 3 h, resulting in low or undetectable levels in most patients. However, in patients receiving an equivalent dose of paclitaxel given as a 1-h infusion, the plasma alcohol levels will likely be high enough for significant pharmacological effects to occur.Type of Medium: Electronic ResourceURL: -
12Articles: DFG German National LicensesStaff View
ISSN: 1432-0843Keywords: Key words Etoposide ; Multidrug resistance ; ChemosensitizersSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Cremophor EL, a surfactant used in the clinical formulation of cyclosporine and paclitaxel, will reverse the multidrug resistance (MDR) phenotype in vitro. As other MDR modulators can alter the pharmacokinetics of cytotoxic drugs, the aim of this study was to examine the effect of Cremophor and another MDR-reversing surfactant, Tween 80, on the hepatic elimination and biliary excretion of etoposide. Using the isolated perfused rat-liver model with 80 ml recirculating perfusate containing 20% red blood cells and 4% bovine serum albumin, etoposide (1.6 mg) with and without Cremophor (800 or 80 mg) or Tween 80 (80 mg) was given into the perfusate reservoir, and perfusate and bile samples were collected for 3 h. Etoposide was measured by high-performance liquid chromatography (HPLC) and Cremophor was measured using a bioassay. Both surfactants changed the etoposide elimination profile from biphasic to monophasic. High-dose Cremophor increased the AUC (from 334±23 to 1540±490 μg min ml-1, P〈0.05) and decreased the total clearance (from 4.8±0.3 to 1.1±0.3 ml/min, P〈0.05) and biliary clearance (from 2.6±1.1 to 0.5±0.2 ml/min, P〈0.05) but decreased the elimination half-life (from 62±17 to 40±5 min, P〈0.05) and volume of distribution (from 424±85 to 65±19 ml, P〈0.05). Low-dose Cremophor and Tween 80 caused intermediate effects on these parameters that were statistically significant for total clearance, half-life, and volume of distribution. Cremophor had no adverse effect on liver function, whereas Tween 80 caused haemolysis and cholestasis. The initial high-dose Cremophor perfusate concentration was 0.8 mg/ml, which previous studies have shown to be clinically relevant and close to the optimal level for MDR reversal in vitro (1.0 mg/ml). Cremophor may be a clinically useful MDR modulator, but it may alter the pharmacokinetics of the cytotoxic drug.Type of Medium: Electronic ResourceURL: -
13Articles: DFG German National LicensesStaff View
ISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
14Articles: DFG German National LicensesStaff View
ISSN: 1433-8491Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: